Efficacy and Safety of Vibrating Capsule in Patients With Functional Constipation

Not Applicable

Completed

• Conditions: Functional Constipation; Gastrointestinal Disease; Capsule Endoscopy
• Interventions: Device: Sallowing VC during six weeks

• Registration Number: NCT04671264
• Lead Sponsor: Changhai Hospital

Brief Summary

The safety and efficacy of vibrating capsule (VC) in promoting defecation by mechanical stimulation of the gastrointestinal walls have been elucidated in animal studies and pilot clinical studies. Our study aimed to explore the clinical application of a newly developed smartphone-controlled multi-mode VC in the treatment of functional constipation (FC) on multicentres.

Patients referred to gastroenterology outpatient of Changhai Hospital with FC and met the eligible criteria for more than 6 months and with spontaneous complete bowel movement (SCBM) less than 3 times per week within recent 3 weeks were eligible for this study. The study was discussed with patients who satisfied the enrolment criteria and provided written informed consents.

Detailed Description

This study was a multicentred, double-blind, placebo-controlled clinical trial to assess the safety and the effecacy of a newly developed gastrointestinal vibrating capsule (VC) in treating patients with functional constipation (FC). The whole process included two weeks run-in period, six weeks double-blind, placebo-controlled treatment period, and a follow-up period until the discharge of all swallowed capsules. During treatment period, patients were required to swallow one capsule every three to four days and a total of twelve capsules.

For each patient, a face to face follow-up was required for at least 6 times, once every two weeks through the whole study.

Run-in period (Visit 1) Face to face consultation in gastroenterology outpatient clinic and sign of written informed consents; Barium enema or colonoscopy (no re-examination is needed if the patient has undergone barium enema or total colonoscopy within a year); Distribution of bisacodyl tablets and diary cards; Perform the following examinations: vital signs, physical examination and laboratory examination; Eligibility evaluation based on the entry/discharge criteria; Record of past medical history, concomitant diseases and medication; Collection of the baseline characteristics of the enrolled patients including age, sex, duration of constipation, mean SCBMs, spontaneous bowel movements (SBMs), BMs, frequency of bisacodyl tablets taken and Bristol Score.

Treatment period Visit 2： Randomization; Patients were asked to fill in PAC-SYM, PAC-QOL and Comprehensive Evaluation Questionnaire; Record of vital signs and physical examination; Distribution of bisacodyl tablets, capsule retrieving bags and VCs; Instruct patients how to use the control board and start the vibration of VCs; Recycle of bisacodine tablets; Distribution and collection of diary cards; Record of adverse events, concomitant diseases and medication. Visit 3, Visit 4： Patients were asked to fill in PAC-SYM, PAC-QOL and Comprehensive Evaluation Questionnaire; Record of vital signs and physical examination; Recheck fecal routine and occult blood examination; Distribution of bisacodyl tablets, capsule retrieving bags and VCs; Recycle of bisacodyl tablets and VCs; Distribution and collection of diary cards; Record of adverse events, concomitant diseases and medication. Visit 5： Patients were asked to fill in PAC-SYM, PAC-QOL and Comprehensive Evaluation Questionnaire; Record of vital signs and physical examination; ECG; Blood routine/blood biochemistry/urine routine; Fecal routine and occult blood; Recycle of bisacodyl tablets and VCs; Distribution and collection of diary cards; Distribution of capsule retrieving bags; Record of adverse events, concomitant diseases and medication.

Follow-up period (Visit6):

Determine the discharge of all capsules; Recycle of capsules; Collection of diary cards; During the follow-up period, once the capsule was discharged the follow-up would be ended. If the capsules were still in the body, the patients must continue the follow-up until the capsules were all discharged.

The primary endpoint was the proportion of patients with SBM increased more than 1 time during treatment period. Secondary endpoints including mean SCBM , SBM , bowel movement (BM) and their improvements , Bristol Score, capsule evacuation time and satisfaction level. Patients were continuously monitored for adverse events (AE) at baseline and at each visit. Satisfaction level were evaluated based on Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL) and Patient Assessment of Constipation Symptom (PAC-SYM) at each visit.

Study Timeline

• Study Start: 2018-11-14
• Primary Completion: 2020-05-11
• Study Completion: 2020-10-30
• Status Verified: 2020-12
• Study First Submitted: 2020-12-03
• Study First Submitted QC: 2020-12-11
• Last Update Submitted: 2020-12-11
• Study First Posted: 2020-12-17
• Last Update Posted: 2020-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

• Male and female patients aged over 18 years and under 80 years;

• Patients who present with chronic constipation for more than 6 months and with SBM less than 3 times per week within recent 3 weeks and have at least one of the following symptoms for more than one-fourth (25%) during defecation:

  1. Straining;
  2. Lumpy or hard stools (bristol stool form (BSF scale 1~2);
  3. Sensation of incomplete evacuation;
  4. Sensation of anorectal obstruction/blockage;
  5. Manual maneuvers to facilitate defecation. Note: The above criteria can only be applied during spontaneous defecation, including no taking of laxatives within 24 hours before defecation, etc.

• Organic diseases were not found by barium enema or colonoscopy in the past year.

• Insufficient criteria for irritable bowel syndrome.

Exclusion Criteria

• Patients who have contraindications to gastroscopy or colonoscopy;
• Patients under 18 years or over 80 years;
• Active vomiting;
• Patients with a permanent pacemaker (e.g. implantable cardioverter-defibrillator);
• Patients with any electronic/magnetic/mechanically controlled devices (e.g. sacral nerve stimulators, bladder stimulators);
• Patients with dysphagia, odynophagia or known swallowing disorder;
• Patients with known Zenker's diverticulum;
• Patients with suspected bowel obstruction or bowel perforation;
• Patients with prior bowel obstruction;
• Patients with gastroparesis or known gastric outlet obstruction;
• Patients with known Crohn's disease;
• Patients who are taking daily non-steroidal anti-inflammatory drugs (excluding prophylactic doses of aspirin) for more than six months;
• Patients who have received abdominopelvic radiotherapy treatment;
• Patients with a history of GI tract surgery (Billroth I, Billroth II, Oesophagectomy, gastrectomy or bariatric procedure);
• Patients who are pregnant or lactating;
• Patients with altered mental status that would limit their ability to swallow;
• Patients with allergy to conscious sedation, polyethylene glycol or metoclopramide;
• Patients unwilling to swallow the capsule;
• Patients with known dementia affecting ability to consent;
• Patients who have warning signs in recent years including abnormal weight loss(>10% in recent 3 month), bloody stool (except hemorrhoids), infection, etc.;
• Other inappropriate situations determined by physicians.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VC group	Sallowing VC during six weeks	Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight. Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application.
Control group	Sallowing VC during six weeks	The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.

Primary Outcome Measures

Name	Time	Method
The proportion of patients with the increasing of SCBMs during treatment period≥1	Up to 6 weeks	Based on diary card, researchers knew the total times of SCBMs during treatment period. The number divided by the treatment days and multiplied by 7 were the mean SCBMs per week in treatment period. Researcher compared the mean SCBMs per week with SCBMs in baseline period. "Spontaneous" suggested that no laxatives and enema were taken within 24 hours before defecation.

Secondary Outcome Measures

Name	Time	Method
Bristol Score during treatment period	Up to 6 weeks	Stool consistency score using Bristol Stool Form Scale (median, range)-1 for hard lumps to 7 for watery stools.
Incidence of adverse events	Up to 8 weeks	The safety were assessed by the adverse events occured during this study.
Increase of SBMs from baseline to treatment period	Up to 6 weeks	SBM means spontaneous bowel movement.
Increase of PAC-QOL score from baseline to treatment period	Up to 6 weeks	The PAC-QOLquestionnaire contains 28 items grouped into 4 subscales (Values, 2005) covering: Worries and concerns (11 items), Physical discomfort (4 items), Psychosocial discomfort (8 items), and Satisfaction of treatment (5 items).; A 5-point Likert response scale, ranging from 0 (Not at all / none of the time) to 4 (Extremely / All of the time), is used over a 2-week run in period and 6-week treatment period.
The proportion of patients with the increasing of PAC-QOL score during treatment period≥1	Up to 6 weeks	At each visit, patients were asked to fill the PAC -QOL questionnaire. The score of PAC-QOL questionnaire in 6-week treatment period were the mean score of three times.
Increase of SCBMs from baseline to treatment period	Up to 6 weeks	Based on diary card, researchers knew the SCBMs per week during treatment period. Researchers compared them with SCBMs in baseline period.
The proportion of patients with the increasing of SCBMs ≥1 in at least 4 weeks	Up to 6 weeks	Based on diary card, researchers knew the SCBMs of each week. We compared them with SCBMs in baseline period.
The proportion of patients with the increasing of PAC-SYM score during treatment period≥1	Up to 6 weeks	The Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire contained 12 items ( Frank, 1999) assigned to 3 subscales: stool symptoms, rectal symptoms, and abdominal symptoms. Items are scored on 5-point Likert scales, with scores ranging from 0 to 4 (0 = 'symptom absent', 1 = 'mild', 2 = 'moderate', 3 = 'severe' and 4 = 'very severe'). The lower the total score, the lower the symptom burden.

Trial Locations

Locations (1)

Changhai Hospital; 🇨🇳 Shanghai, Shanghai, China